Comparative Pharmacology
Head-to-head clinical analysis: FERRISELTZ versus SESQUIENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERRISELTZ versus SESQUIENT.
FERRISELTZ vs SESQUIENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferric iron (Fe3+) from ferric citrate reduces phosphate absorption by forming insoluble ferric phosphate complexes in the gastrointestinal tract, reducing serum phosphate levels. Iron is absorbed and incorporated into hemoglobin.
SESQUIENT is a monoclonal antibody that binds to the IL-23 receptor, inhibiting IL-23-mediated signaling and subsequent activation of inflammatory pathways involved in psoriasis and psoriatic arthritis.
325-650 mg orally once daily; ferrous sulfate 325 mg (equivalent to 65 mg elemental iron).
Intravenous injection of 20 mg/m² body surface area once every 3 weeks.
None Documented
None Documented
Not applicable for iron absorption; serum iron levels peak at 1-2 hours post-dose and decline with a half-life of approximately 6 hours, reflecting gastrointestinal absorption and distribution.
12 hours (range 10-14 h); allows twice-daily dosing in most patients; prolonged in renal impairment
Ferric citrate is primarily eliminated via feces as unabsorbed drug (approximately 70-80%). A small fraction is absorbed and excreted renally (less than 1% of ingested dose).
Renal: 80% unchanged; Biliary/Fecal: 15% as metabolites; 5% other
Category C
Category C
Iron Supplement
Iron Supplement